News Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Nov 10, 2016
Tel Aviv, Israel. Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA), a pharmaceutical company specializing in the development of cannabinoid-based product candidates, signed a non-binding...
-
Nov 3, 2016Simes has extensive experience in the management of pharma companies in the U.S.
Tel Aviv, Israel. Therapix Biosciences, (OTC: THXBY) (TASE: THXBY.TA) the cannabinoid-based drugs, announced its intention to add Mr. Stephen M. Simes to the Company’s board of directors. Simes...
-
Oct 31, 2016The cannabinoid-based tablet will be used in the upcoming, first clinical trial in its program for the treatment of cognitive impairments
Tel Aviv, Israel. Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA) the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced the...
-
Oct 1, 2016
Therapix Biosciences (OTCQB: THXBY) (TASE: THXBY.TA), a clinical-stage pharma company specializing in the development of cannabinoid-based drugs, reported that in its ongoing product portfolio...
-
Jul 4, 2016The technology, developed at the Hebrew University of Jerusalem, facilitates administration and maximal absorption of the active ingredient THC via nasal inhalation
Tel Aviv, Israel. Therapix Biosciences, , (OTCQB: THXBY) (TASE: THXBY.TA), a pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced today that...